US filing accepted for inhaled treprostinil for PAH
This article was originally published in Scrip
United Therapeutics' NDA for its lead developmental product, an inhaled formulation of treprostinil for pulmonary arterial hypertension (PAH), has been accepted by the US FDA.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.